Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02955602 · ClinicalTrials.gov registry record · Phase 2
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT02955602 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 119 participants.
The verdict
NCT02955602, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
Interventions
- DRUG MBX-8025 2 mg Capsule
- DRUG MBX-8025 5 mg Capsule
- DRUG MBX-8025 10 mg Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2016-11-28 |
| Est. Completion | 2019-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02955602
The ClinicalTrials.gov registry entry for NCT02955602 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MBX-8025 2 mg Capsule is the first listed.
NCT02955602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02955602 about?
NCT02955602 is a clinical study titled "Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)". An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
What is the current status of trial NCT02955602?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2016-11-28. Estimated completion is 2019-07-08.
What interventions are being tested in trial NCT02955602?
The interventions under investigation include: MBX-8025 2 mg Capsule (DRUG), MBX-8025 5 mg Capsule (DRUG), MBX-8025 10 mg Capsule (DRUG).
Who is sponsoring clinical trial NCT02955602?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.